Hoang M. Trinh
University of Missouri–Kansas City
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hoang M. Trinh.
Journal of Controlled Release | 2015
Ashim K. Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M. Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery. Chemical and physical treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells. Furthermore, these approaches are often combined to enhance therapeutic indices. It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth. In addition, these treatment modalities are associated with severe side effects and high toxicity which in turn lead to low quality of life. This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis. Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment. These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects. Lowering multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.
Drug Delivery and Translational Research | 2016
Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M. Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K. Mitra
The eye is a distinctive organ with protective anatomy and physiology. Several pharmacokinetics compartment models of ocular drug delivery have been developed for describing the absorption, distribution, and elimination of ocular drugs in the eye. Determining pharmacokinetics parameters in ocular tissues is a major challenge because of the complex anatomy and dynamic physiological barrier of the eye. In this review, pharmacokinetics of these compartments exploring different drugs, delivery systems, and routes of administration is discussed including factors affecting intraocular bioavailability. Factors such as precorneal fluid drainage, drug binding to tear proteins, systemic drug absorption, corneal factors, melanin binding, and drug metabolism render ocular delivery challenging and are elaborated in this manuscript. Several compartment models are discussed; these are developed in ocular drug delivery to study the pharmacokinetics parameters. There are several transporters present in both anterior and posterior segments of the eye which play a significant role in ocular pharmacokinetics and are summarized briefly. Moreover, several ocular pharmacokinetics animal models and relevant studies are reviewed and discussed in addition to the pharmacokinetics of various ocular formulations.
Expert Opinion on Drug Discovery | 2015
Kishore Cholkar; Hoang M. Trinh; Dhananjay Pal; Ashim K. Mitra
Introduction: Glaucoma is a neurodegenerative disease with heterogeneous causes that result in retinal ganglionic cell (RGC) death. The discovery of ocular antihypertensives has shifted glaucoma therapy, largely, from surgery to medical intervention. Indeed, several intraocular pressure (IOP)-lowering drugs, with different mechanisms of action and RGC protective property, have been developed. Areas covered: In this review, the authors discuss the main new class of kinase inhibitors used as glaucoma treatments, which lower IOP by enhancing drainage and/or lowering production of aqueous humor. The authors include novel inhibitors under preclinical evaluation and investigation for their anti-glaucoma treatment. Additionally, the authors look at treatments that are in clinics now and which may be available in the near future. Expert opinion: Treatment of glaucoma remains challenging because the exact cause is yet to be delineated. Neuroprotection to the optic nerve head is undisputable. The novel Rho-associated kinase inhibitors have the capacity to lower IOP and provide optic nerve and RGC protection. In particular, the S-isomer of roscovitine has the capacity to lower IOP and provide neuroprotection. Combinations of selected drugs, which can provide maximal and sustained IOP-lowering effects as well as neuroprotection, are paramount to the prevention of glaucoma progression. In the near future, microRNA intervention may be considered as a potential therapeutic target.
Expert Opinion on Drug Delivery | 2017
Mary Joseph; Hoang M. Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K. Mitra
ABSTRACT Introduction: Biologics are generally macromolecules, large in size with poor stability in biological environments. Delivery of biologics to tissues at the back of the eye remains a challenge. To overcome these challenges and treat posterior ocular diseases, several novel approaches have been developed. Nanotechnology-based delivery systems, like drug encapsulation technology, macromolecule implants and gene delivery are under investigation. We provide an overview of emerging technologies for biologics delivery to back of the eye tissues. Moreover, new biologic drugs currently in clinical trials for ocular neovascular diseases have been discussed. Areas covered: Anatomy of the eye, posterior segment disease and diagnosis, barriers to biologic delivery, ocular pharmacokinetic, novel biologic delivery system Expert opinion: Anti-VEGF therapy represents a significant advance in developing biologics for the treatment of ocular neovascular diseases. Various strategies for biologic delivery to posterior ocular tissues are under development with some in early or late stages of clinical trials. Despite significant progress in the delivery of biologics, there is unmet need to develop sustained delivery of biologics with nearly zero-order release kinetics to the back of the eye tissues. In addition, elevated intraocular pressure associated with frequent intravitreal injections of macromolecules is another concern that needs to be addressed.
Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices | 2017
Mary Joseph; Hoang M. Trinh; Ashim K. Mitra
Peptides and proteins are naturally occurring large molecules that perform different functions and events to ensure proper functioning of the body. Peptides and protein therapeutics have gained much attention in recent years. Although peptide and protein therapeutics possess high impact in the health industry, delivery of these molecules is limited due to several factors such as large size, hydrophilic nature, and enzymatic cleavage. In this chapter various peptide and protein therapeutics have been debated. Moreover, challenges associated with the delivery of these macromolecules have been provided. Effect of glycosylation, mannosylation, and PEGylation on protein and peptides is also included. Finally, different colloidal delivery systems that may be used to deliver macromolecules have been discussed.
Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices | 2017
Kishore Cholkar; Gayathri Acharya; Hoang M. Trinh; Gagandeep Singh
Polymers (natural and synthetic) are widely employed in imaging, diagnosis, and delivery. Drug delivery polymers are engineered into a vesicular carrier system such as microparticles, nanoparticles, implants, or scaffolds to encapsulate drugs for sustained release. In this chapter we made attempts to discuss the applications of polymers in various biomedical applications particularly therapeutics.
Drug Delivery | 2015
Xiaoyan Yang; Ye Sheng; Animikh Ray; Sujay Shah; Hoang M. Trinh; Dhananjay Pal; Ashim K. Mitra
Abstract Purpose: The objective of this study is to investigate cellular uptake of prodrug-loaded nanoparticle (NP). Another objective is to study bioconversion of stereoisomeric dipeptide prodrugs of ganciclovir (GCV) including L-Val-L-Val-GCV (LLGCV), L-Val-D-Val-GCV (LDGCV) and d-Val-l-Val-GCV (DLGCV) in human corneal epithelial cell (HCEC) model. Methods: Poly(D,L-lactic-co-glycolic acid) (PLGA) NP encapsulating prodrugs of GCV were formulated under a double emulsion method. Fluorescein isothiocyanate isomer–PLGA conjugates were synthesized to fabricate biocompatible fluorescent PLGA NP. Intracellular uptake of FITC-labeled NP was visualized by a fluorescent microscope in HCEC cells. Results: Fluorescent PLGA NP and non-fluorescent NP display similar hydrodynamic diameter in the range of 115–145 nm with a narrow particle size distribution and zeta potentials around −13 mV. Both NP types showed identical intracellular accumulation in HCEC cells. Maximum uptake (around 60%) was noted at 3 h for NP. Cellular uptake and intracellular accumulation of prodrugs are significantly different among three stereoisomeric dipeptide prodrugs. The microscopic images show that NPs are avidly internalized by HCEC cells and distributed throughout the cytoplasm instead of being localized on the cell surface. Following cellular uptake, prodrugs released from NP gradually bioreversed into parent drug GCV. LLGCV showed the highest degradation rate, followed by LDGCV and DLGCV. Conclusion: LLGCV, LDGCV and DLGCV released from NP exhibited superior uptake and bioreversion in corneal cells.
Aaps Pharmscitech | 2016
Xiaoyan Yang; Hoang M. Trinh; Vibhuti Agrahari; Ye Sheng; Dhananjay Pal; Ashim K. Mitra
Advances in Ophthalmology & Visual System | 2014
Kishore Cholkar; Hoang M. Trinh; Aswani Dutt Vadlapudi; Ashim K. Mitra
Archive | 2013
Kishore Cholkar; Aswani Dutt Vadlapudi; Hoang M. Trinh; Ashim K. Mitra